<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/GettyImages-2260256868-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/GettyImages-2260256868-430x241.jpg"/></p>
<p>葛蘭素史克的疫苗自 2015 年以來一直在英國的嬰兒常規免疫計劃中使用，並導致接種年齡組的感染減少了 75%。照片由 Nikolas Kokovlis/NurPhoto 通過 Getty Images 提供。</p>
<p>在英格蘭肯特地區持續爆發腦膜炎球菌病的情況下，葛蘭素史克表示，如果需要，將準備與英國衞生當局合作，擴大其腦膜炎疫苗在國家免疫計劃中的使用。</p>
<p>該製藥公司的 MenB 疫苗，品牌名為 Bexsero，目前僅在英國的嬰兒免疫計劃中使用。自 2015 年以來，它一直被納入英國的嬰兒常規免疫計劃。然而，這意味着許多人，包括在此日期之前出生的青少年，除非私下接種疫苗，否則沒有得到保護。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: GSK plc 的 AFX-3772</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: GSK plc 的 Men ABCWY</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現有效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>肯特一所大學的腦膜炎球菌病持續爆發，導致政府正在評估疫苗的更廣泛使用。此次疫情導致兩人死亡，20 個潛在病例。英國衞生安全局（UKHSA）表示，將啓動針對性疫苗接種計劃，首先針對居住在肯特大學的學生。衞生部長 Wes Streeting 在下議院表示，他將要求政府顧問考慮將現有免疫計劃擴展到嬰兒以外的年齡組，例如青少年。</p>
<p>葛蘭素史克的一位發言人告訴《製藥技術》：&#34;我們準備與英國衞生當局就 MenB 疫苗/Bexsero 的更廣泛使用進行接洽，以應對肯特的當前疫情。任何此類提案的細節尚未確定，因此我們目前無法進一步評論。&#34;</p>
<p>腦膜炎球菌病是由侵襲性感染引起的，病原體為_奈瑟氏腦膜炎球菌_。細菌通過呼吸道分泌物的呼氣飛沫或與感染者的呼吸道分泌物直接接觸傳播。青少年羣體，如學生，由於社交文化和羣居生活安排，感染風險更高。</p>
<p>MenB 疫苗通過兩劑接種，自 2015 年以來一直在英國的嬰兒常規免疫計劃中使用，並導致接種組的感染減少了 75%。Bexsero 旨在對導致腦膜炎球菌病的大多數 MenB 菌株提供廣泛的保護，儘管由於新突變的出現，它無法提供完全的保護。</p>
<p>抗生素仍然是限制侵襲性腦膜炎球菌病傳播的最有效治療方法。UKHSA 表示，肯特地區已向學生及其密切接觸者提供了超過 2500 劑疫苗。</p>
<p>在評論當前疫情時，UKHSA 的負責人 Susan Hopkins 表示：&#34;這看起來像是一個超級傳播事件，正在大學宿舍內持續傳播。&#34;</p>
<h2>私營部門的供應減少</h2>
<p>自 2013 年疫苗首次獲批以來，葛蘭素史克的 MenB 疫苗也一直可以私下接種。自肯特疫情以來，私人診所和藥店報告了對該疫苗需求的激增。</p>
<p>一位希望保持匿名的倫敦私人診所的全科醫生告訴《製藥技術》：&#34;我們接到大量電話。我們所有的疫苗供應現在都用完了，無法再獲得更多。&#34;</p>
<p>該診所表示收到了來自其醫療供應商的警報，稱：&#34;我們已經售罄 Bexsero 疫苗。目前，我們不知道何時能夠獲得更多，因為優先權給予 NHS。&#34;</p>
<p>與此同時，連鎖藥店 Superdrug 報告稱，疫苗的預約需求增加了 65 倍。</p>
<p>“目前腦膜炎 B 疫苗存在全國性短缺，庫存有限。我們正在與供應商合作以確保更多劑量，” 該公司在一份聲明中表示。</p>

葛蘭素史克

<p>葛蘭素史克（GSK）準備在英國肯特地區的腦膜炎球菌疾病爆發期間擴大其腦膜炎疫苗接種計劃。衞生部長韋斯·斯特里廷（Wes Streeting）正在考慮將疫苗的接種範圍擴大到青少年，因為目前的接種計劃僅覆蓋嬰兒。MenB 疫苗 Bexsero 自 2015 年以來已成為英國免疫計劃的一部分，感染率降低了 75%。目前已報告兩例死亡和 20 例潛在病例，針對大學生的定向接種計劃即將開始。疫苗需求激增，導致私人診所和藥店出現短缺</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/GettyImages-2260256868-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/GettyImages-2260256868-430x241.jpg"/></p>
<p>GSK’s vaccine has been on the UK’s routine immunisation programme for babies since 2015 and has led to a 75% reduction in infections in vaccinated age groups. Photo by Nikolas Kokovlis/NurPhoto via Getty Images.</p>
<div class="lb-trans"><p>葛蘭素史克的疫苗自 2015 年以來一直在英國的嬰兒常規免疫計劃中使用，並導致接種年齡組的感染減少了 75%。照片由 Nikolas Kokovlis/NurPhoto 通過 Getty Images 提供。</p>
</div><p>Amid an ongoing outbreak of meningococcal disease in Kent, England, GSK has said it is ready to work with UK health authorities to widen its meningitis vaccine’s slot on the country’s immunisation schedule, if needed.</p>
<div class="lb-trans"><p>在英格蘭肯特地區持續爆發腦膜炎球菌病的情況下，葛蘭素史克表示，如果需要，將準備與英國衞生當局合作，擴大其腦膜炎疫苗在國家免疫計劃中的使用。</p>
</div><p>The drugmaker’s MenB vaccine, known under the brand name Bexsero, is currently on the UK schedule for infants only.  It has been used in the UK’s routine immunisation programme for babies since 2015. However, this means many people, including teenagers born before this date, are not protected unless they obtained the vaccine privately.</p>
<div class="lb-trans"><p>該製藥公司的 MenB 疫苗，品牌名為 Bexsero，目前僅在英國的嬰兒免疫計劃中使用。自 2015 年以來，它一直被納入英國的嬰兒常規免疫計劃。然而，這意味着許多人，包括在此日期之前出生的青少年，除非私下接種疫苗，否則沒有得到保護。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: GSK plc's AFX-3772</h4>
<div class="lb-trans"><h4>NPVM: GSK plc 的 AFX-3772</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: GSK plc's Men ABCWY</h4>
<div class="lb-trans"><h4>NPVM: GSK plc 的 Men ABCWY</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現有效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>An ongoing outbreak of meningococcal disease at a university in Kent has meant the government is evaluating the vaccine’s broader use. Two people have died as a result of the outbreak, with 20 potential cases.  The UK Health Security Agency (UKHSA) said that a targeted vaccination programme will begin, starting with students residing at the University of Kent. Health secretary Wes Streeting said in the House of Commons that he would ask government advisers to consider expanding the existing schedule to age groups beyond infants, such as teenagers.</p>
<div class="lb-trans"><p>肯特一所大學的腦膜炎球菌病持續爆發，導致政府正在評估疫苗的更廣泛使用。此次疫情導致兩人死亡，20 個潛在病例。英國衞生安全局（UKHSA）表示，將啓動針對性疫苗接種計劃，首先針對居住在肯特大學的學生。衞生部長 Wes Streeting 在下議院表示，他將要求政府顧問考慮將現有免疫計劃擴展到嬰兒以外的年齡組，例如青少年。</p>
</div><p>A GSK spokesperson told <em>Pharmaceutical Technology</em>: “We are ready to engage with any proposals from UK health authorities regarding the broader use of MenB vaccination/Bexsero, to address the current outbreak in Kent. The details of any such proposals are not yet established and so we cannot comment further at this stage.”</p>
<div class="lb-trans"><p>葛蘭素史克的一位發言人告訴《製藥技術》：&#34;我們準備與英國衞生當局就 MenB 疫苗/Bexsero 的更廣泛使用進行接洽，以應對肯特的當前疫情。任何此類提案的細節尚未確定，因此我們目前無法進一步評論。&#34;</p>
</div><p>Meningococcal disease is caused by invasive infection with the bacterium <em>Neisseria meningitidis</em>. The bacteria are transmitted by exhaled droplets or by direct contact with the respiratory secretions of an infected individual. Teenage groups, such as students, are at higher risk of infection because of social culture and group-living arrangements.</p>
<div class="lb-trans"><p>腦膜炎球菌病是由侵襲性感染引起的，病原體為_奈瑟氏腦膜炎球菌_。細菌通過呼吸道分泌物的呼氣飛沫或與感染者的呼吸道分泌物直接接觸傳播。青少年羣體，如學生，由於社交文化和羣居生活安排，感染風險更高。</p>
</div><p>The MenB vaccine, administered via two doses, has been on the UK routine immunisation programme for babies since 2015 and has led to a 75% reduction in infections for vaccinated groups. Bexsero has been designed to offer broad coverage against most MenB strains causing meningococcal disease, though it cannot offer complete protection, given that new mutations arise.</p>
<div class="lb-trans"><p>MenB 疫苗通過兩劑接種，自 2015 年以來一直在英國的嬰兒常規免疫計劃中使用，並導致接種組的感染減少了 75%。Bexsero 旨在對導致腦膜炎球菌病的大多數 MenB 菌株提供廣泛的保護，儘管由於新突變的出現，它無法提供完全的保護。</p>
</div><p>Antibiotics remain the most effective treatment to limit the spread of invasive meningococcal disease. The UKHSA said that over 2,500 doses have been given to students, along with their close contacts, in the Kent area.</p>
<div class="lb-trans"><p>抗生素仍然是限制侵襲性腦膜炎球菌病傳播的最有效治療方法。UKHSA 表示，肯特地區已向學生及其密切接觸者提供了超過 2500 劑疫苗。</p>
</div><p>Commenting on the ongoing outbreak, the UKHSA’s chief, Susan Hopkins, said: “This looks like a superspreader event, with ongoing spread within the halls of residents in the universities.”</p>
<div class="lb-trans"><p>在評論當前疫情時，UKHSA 的負責人 Susan Hopkins 表示：&#34;這看起來像是一個超級傳播事件，正在大學宿舍內持續傳播。&#34;</p>
</div><h2>Private sector’s diminishing supply</h2>
<div class="lb-trans"><h2>私營部門的供應減少</h2>
</div><p>GSK’s MenB vaccine has also been available privately since the jab’s original approval in 2013. Both private surgeries and pharmacies have reported a surge in demand for the vaccine since the outbreak in Kent.</p>
<div class="lb-trans"><p>自 2013 年疫苗首次獲批以來，葛蘭素史克的 MenB 疫苗也一直可以私下接種。自肯特疫情以來，私人診所和藥店報告了對該疫苗需求的激增。</p>
</div><p>A GP at a private surgery in London, who wished to remain anonymous, told <em>Pharmaceutical Technology</em>: “We’re being inundated with calls. All our vaccine supplies are now used up and we can’t get any more.”</p>
<div class="lb-trans"><p>一位希望保持匿名的倫敦私人診所的全科醫生告訴《製藥技術》：&#34;我們接到大量電話。我們所有的疫苗供應現在都用完了，無法再獲得更多。&#34;</p>
</div><p>The surgery said it received an alert from its medical supplier, stating: “We have sold out of Bexsero vaccines. Currently, we don’t know when we will be able to get more as priority is given to the NHS.”</p>
<div class="lb-trans"><p>該診所表示收到了來自其醫療供應商的警報，稱：&#34;我們已經售罄 Bexsero 疫苗。目前，我們不知道何時能夠獲得更多，因為優先權給予 NHS。&#34;</p>
</div><p>Meanwhile, high-street pharmacy chain Superdrug reported a 65-fold increase in booking demand for the vaccine.</p>
<div class="lb-trans"><p>與此同時，連鎖藥店 Superdrug 報告稱，疫苗的預約需求增加了 65 倍。</p>
</div><p>“There is currently a national shortage of the Meningitis B vaccine, and stock is limited. We are working with suppliers to secure more doses,” the company said in a statement.</p>
<div class="lb-trans"><p>“目前腦膜炎 B 疫苗存在全國性短缺，庫存有限。我們正在與供應商合作以確保更多劑量，” 該公司在一份聲明中表示。</p>
</div>

葛蘭素史克準備在英國爆發期間擴展腦膜炎疫苗接種計劃